

NMR LipoProfile w/lipids

| NAME | VALUE | REFERENCE RANGE | LAB |
|--|-------|-----------------------------|-----|
| F LDL-P | 856 | <1000 (nmol/L) | BN |
| - | | Low < 1000 | |
| - | | Moderate 1000 - 1299 | |
| - | | Borderline-High 1300 - 1599 | |
| - | | High 1600 - 2000 | |
| - | | Very High > 2000 | |
| F LDL-C | 64 | 0-99 (mg/dL) | BN |
| - | | . | |
| - | | Optimal < 100 | |
| - | | Above optimal 100 - 129 | |
| - | | Borderline 130 - 159 | |
| - | | High 160 - 189 | |
| - | | Very high > 189 | |
| - | | . | |
| - LDL-C is inaccurate if patient is non-fasting. | | | |
| F HDL-C | 59 | >39 (mg/dL) | BN |
| F Triglycerides | 130 | 0-149 (mg/dL) | BN |
| F Cholesterol, Total | 149 | 100-199 (mg/dL) | BN |
| F HDL-P (Total) | 41.2 | >=30.5 (umol/L) | BN |
| F Small LDL-P | 418 | <=527 (nmol/L) | BN |
| F LDL Size | 21.4 | >20.5 (nm) | BN |
| - | ----- | | |
| - | | | |

**** INTERPRETATIVE INFORMATION****

- PARTICLE CONCENTRATION AND SIZE

- <--Lower CVD Risk Higher CVD Risk-->

- LDL AND HDL PARTICLES Percentile in Reference Population

| | | | | | |
|------------------------|-----------------|-------------|-------------|-------------|-----------------|
| - HDL-P (total) | High | 75th | 50th | 25th | Low |
| | >34.9 | 34.9 | 30.5 | 26.7 | <26.7 |

- .

| | | | | | |
|----------------------|------------|-------------|-------------|-------------|-------------|
| - Small LDL-P | Low | 25th | 50th | 75th | High |
|----------------------|------------|-------------|-------------|-------------|-------------|

| | | | | | |
|--|----------------|------------|------------|------------|----------------|
| | <117 | 117 | 527 | 839 | >839 |
|--|----------------|------------|------------|------------|----------------|

- .

| | | |
|-------------------|------------------------------------|------------------------------------|
| - LDL Size | <-Large (Pattern A)-> | <-Small (Pattern B)-> |
|-------------------|------------------------------------|------------------------------------|

| | | | | |
|--|-------------|-------------|-------------|-------------|
| | 23.0 | 20.6 | 20.5 | 19.0 |
|--|-------------|-------------|-------------|-------------|

- -----

- Small LDL-P and LDL Size are associated with CVD risk, but not after

- LDL-P is taken into account.

F LP-IR Score 49 H <=45 BN

- INSULIN RESISTANCE MARKER

- <--Insulin Sensitive Insulin Resistant-->

- Percentile in Reference Population

- Insulin Resistance Score

| | | | | | |
|----------------------|------------|-------------|-------------|-------------|-------------|
| - LP-IR Score | Low | 25th | 50th | 75th | High |
|----------------------|------------|-------------|-------------|-------------|-------------|

| | | | | | |
|--|---------------|-----------|-----------|-----------|---------------|
| | <27 | 27 | 45 | 63 | >63 |
|--|---------------|-----------|-----------|-----------|---------------|

- LP-IR Score is inaccurate if patient is non-fasting.

- .

- The LP-IR score is a laboratory developed index that has been

- associated with insulin resistance and diabetes risk and should be

- used as one component of a physician's clinical assessment.

Insulin

| NAME | VALUE | REFERENCE RANGE | LAB |
|-----------|--------|-------------------|-------|
| F Insulin | 32.3 H | 2.6-24.9 (uIU/mL) | PDLCA |

Hemoglobin A1c

| NAME | VALUE | REFERENCE RANGE | LAB |
|------------------|-------|-----------------|-------|
| F Hemoglobin A1c | 5.3 | 4.8-5.6 (%) | PDLCA |

Microalb/Creat Ratio, Randm Ur

| NAME | VALUE | REFERENCE RANGE | LAB |
|---------------------|-----------------------|-----------------------|-------|
| F Creatinine, Urine | 23.4 | Not Estab. (mg/dL) | PDLCA |
| F Albumin, Urine | <3.0 | Not Estab. (ug/mL) | PDLCA |
| F Alb/Creat Ratio | <12.8 | 0.0-30.0 (mg/g creat) | PDLCA |
| - | Normal: | 0.0 - 30.0 | |
| - | Albuminuria: | 31.0 - 300.0 | |
| - | Clinical albuminuria: | >300.0 | |

Urinalysis, Routine with Reflex to Culture & Sensitivity

| NAME | VALUE | REFERENCE RANGE | LAB |
|--------------------|--------|-----------------|-------|
| F Specific Gravity | 1.006 | 1.005-1.030 | PDLCA |
| F pH | 6.0 | 5.0-7.5 | PDLCA |
| F Urine-Color | Yellow | Yellow | PDLCA |
| F Appearance | Clear | Clear | PDLCA |

| | | | | |
|---|-------------------------|----------|-----------------|-------|
| F | WBC Esterase | Negative | Negative | PDLCA |
| F | Protein | Negative | Negative/Trace | PDLCA |
| F | Glucose | Negative | Negative | PDLCA |
| F | Ketones | Negative | Negative | PDLCA |
| F | Occult Blood | Negative | Negative | PDLCA |
| F | Bilirubin | Negative | Negative | PDLCA |
| F | Urobilinogen,Semi-Qn | 0.2 | 0.2-1.0 (mg/dL) | PDLCA |
| F | Nitrite, Urine | Negative | Negative | PDLCA |
| F | Microscopic Examination | | | |

Comp. Metabolic Panel (14)

| | NAME | VALUE | REFERENCE RANGE | LAB |
|---|-----------------------|-------|-------------------|-------|
| F | Glucose | 109 H | 65-99 (mg/dL) | PDLCA |
| F | BUN | 15 | 6-24 (mg/dL) | PDLCA |
| F | Creatinine | 0.97 | 0.76-1.27 (mg/dL) | PDLCA |
| F | eGFR If NonAfricn Am | 91 | >59 (mL/min/1.73) | PDLCA |
| F | eGFR If Africn Am | 105 | >59 (mL/min/1.73) | PDLCA |
| F | BUN/Creatinine Ratio | 15 | 9-20 | PDLCA |
| F | Sodium | 142 | 134-144 (mmol/L) | PDLCA |
| F | Potassium | 4.2 | 3.5-5.2 (mmol/L) | PDLCA |
| F | Chloride | 105 | 96-106 (mmol/L) | PDLCA |
| F | Carbon Dioxide, Total | 20 | 20-29 (mmol/L) | PDLCA |
| F | Calcium | 9.7 | 8.7-10.2 (mg/dL) | PDLCA |
| F | Protein, Total | 7.2 | 6.0-8.5 (g/dL) | PDLCA |
| F | Albumin | 4.6 | 3.5-5.5 (g/dL) | PDLCA |

| | | | | |
|---|----------------------|-----|-----------------|-------|
| F | Globulin, Total | 2.6 | 1.5-4.5 (g/dL) | PDLCA |
| F | A/G Ratio | 1.8 | 1.2-2.2 | PDLCA |
| F | Bilirubin, Total | 0.4 | 0.0-1.2 (mg/dL) | PDLCA |
| F | Alkaline Phosphatase | 54 | 39-117 (IU/L) | PDLCA |
| F | AST (SGOT) | 18 | 0-40 (IU/L) | PDLCA |
| F | ALT (SGPT) | 23 | 0-44 (IU/L) | PDLCA |

Progesterone

| | NAME | VALUE | REFERENCE RANGE | LAB |
|---|--------------|-------|-----------------|-------|
| F | Progesterone | 0.2 | 0.0-0.5 (ng/mL) | PDLCA |

Testosterone, Free+Total LC/MS

| | NAME | VALUE | REFERENCE RANGE | LAB |
|---|-----------------------------|-------|---------------------|-----|
| F | -Testosterone, Total, LC/MS | 338.1 | 264.0-916.0 (ng/dL) | BN |

- This LabCorp LC/MS-MS method is currently certified by the CDC
- Hormone Standardization Program (HoSt). Adult male reference
- interval is based on a population of healthy nonobese males
- (BMI <30) between 19 and 39 years old. Travison, et.al. JCEM
- 2017,102;1161-1173. PMID: 28324103.

| | | | | |
|---|---------------------------|------|------------------|----|
| F | Free Testosterone(Direct) | 13.9 | 7.2-24.0 (pg/mL) | BN |
|---|---------------------------|------|------------------|----|

Estrogens, Total

| | NAME | VALUE | REFERENCE RANGE | LAB |
|---|------------------|-------|-----------------|-----|
| F | Estrogens, Total | 115 | 40-115 (pg/mL) | BN |

Estradiol

| | NAME | VALUE | REFERENCE RANGE | LAB |
|---|-----------|--------|------------------|-------|
| F | Estradiol | 74.9 H | 7.6-42.6 (pg/mL) | PDLCA |

- Roche ECLIA methodology

CBC With Differential/Platelet

| NAME | VALUE | REFERENCE RANGE | LAB |
|--------------------------|-------|----------------------|-------|
| F WBC | 4.9 | 3.4-10.8 (x10E3/uL) | PDLCA |
| F RBC | 5.20 | 4.14-5.80 (x10E6/uL) | PDLCA |
| F Hemoglobin | 16.2 | 13.0-17.7 (g/dL) | PDLCA |
| F Hematocrit | 47.8 | 37.5-51.0 (%) | PDLCA |
| F MCV | 92 | 79-97 (fL) | PDLCA |
| F MCH | 31.2 | 26.6-33.0 (pg) | PDLCA |
| F MCHC | 33.9 | 31.5-35.7 (g/dL) | PDLCA |
| F RDW | 14.2 | 12.3-15.4 (%) | PDLCA |
| F Platelets | 182 | 150-450 (x10E3/uL) | PDLCA |
| F Neutrophils | 57 | Not Estab. (%) | PDLCA |
| F Lymphs | 33 | Not Estab. (%) | PDLCA |
| F Monocytes | 8 | Not Estab. (%) | PDLCA |
| F Eos | 2 | Not Estab. (%) | PDLCA |
| F Basos | 0 | Not Estab. (%) | PDLCA |
| Immature Cells | | | PDLCA |
| F Neutrophils (Absolute) | 2.8 | 1.4-7.0 (x10E3/uL) | PDLCA |
| F Lymphs (Absolute) | 1.6 | 0.7-3.1 (x10E3/uL) | PDLCA |
| F Monocytes(Absolute) | 0.4 | 0.1-0.9 (x10E3/uL) | PDLCA |
| F Eos (Absolute) | 0.1 | 0.0-0.4 (x10E3/uL) | PDLCA |
| F Baso (Absolute) | 0.0 | 0.0-0.2 (x10E3/uL) | PDLCA |
| F Immature Granulocytes | 0 | Not Estab. (%) | PDLCA |
| F Immature Grans (Abs) | 0.0 | 0.0-0.1 (x10E3/uL) | PDLCA |

NRBC

PDLCA

Hematology Comments:

PDLCA

Pregnenolone, MS

| NAME | VALUE | LAB |
|--------------------|------------|-----|
| F Pregnenolone, MS | 17 (ng/dL) | ES |

Reference Range:

Adults: <151

Prolactin

| NAME | VALUE | REFERENCE RANGE | LAB |
|-------------|-------|------------------|-------|
| F Prolactin | 4.5 | 4.0-15.2 (ng/mL) | PDLCA |

FSH and LH

| NAME | VALUE | REFERENCE RANGE | LAB |
|-------|-------|-------------------|-------|
| F LH | 3.4 | 1.7-8.6 (mIU/mL) | PDLCA |
| F FSH | 3.8 | 1.5-12.4 (mIU/mL) | PDLCA |

DHEA, Serum

| NAME | VALUE | REFERENCE RANGE | LAB |
|---------------------------------|-------|-----------------|-----|
| F Dehydroepiandrosterone (DHEA) | 216 | 31-701 (ng/dL) | BN |

| | | |
|---|---------------|----------|
| - | Age | |
| - | 1 - 5 years | 0 - 67 |
| - | 6 - 7 years | 0 - 110 |
| - | 8 - 10 years | 0 - 185 |
| - | 11 - 12 years | 0 - 201 |
| - | 13 - 14 years | 0 - 318 |
| - | 15 - 16 years | 39 - 481 |

| | | |
|---|---------------|----------|
| - | 17 - 19 years | 40 - 491 |
| - | >19 years | 31 - 701 |

Thyroid Panel With TSH

| NAME | VALUE | REFERENCE RANGE | LAB |
|------------------------|-------|----------------------|-------|
| F TSH | 2.380 | 0.450-4.500 (uIU/mL) | PDLCA |
| F Thyroxine (T4) | 6.8 | 4.5-12.0 (ug/dL) | PDLCA |
| F T3 Uptake | 26 | 24-39 (%) | PDLCA |
| F Free Thyroxine Index | 1.8 | 1.2-4.9 | PDLCA |

T4+Free T4

| NAME | VALUE | LAB |
|--------------------------|-------------|-----|
| F Thyroxine (T-4), Serum | 6.8 (ug/dL) | ES |

Reference Range:

Adults: 4.2 - 13.0

| | | |
|---------------------------------|-------------|----|
| F Free T4 by Dialysis/Mass Spec | 1.1 (ng/dL) | ES |
|---------------------------------|-------------|----|

Reference Range:

Pubertal Children and Adults:

0.8 - 1.7

Reverse T3, Serum

| NAME | VALUE | REFERENCE RANGE | LAB |
|---------------------|-------|------------------|-----|
| F Reverse T3, Serum | 12.7 | 9.2-24.1 (ng/dL) | BN |

- This test was developed and its performance characteristics
- determined by LabCorp. It has not been cleared or approved
- by the Food and Drug Administration.

PSA Total+ Free (Serial)

| NAME | VALUE | REFERENCE RANGE | LAB |
|-------------------------------|-------|-----------------|-------|
| F Prostate Specific Ag, Serum | 0.7 | 0.0-4.0 (ng/mL) | PDLCA |

- Roche ECLIA methodology.

-

- According to the American Urological Association, Serum PSA should
- decrease and remain at undetectable levels after radical
- prostatectomy. The AUA defines biochemical recurrence as an initial
- PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory
- PSA value 0.2 ng/mL or greater.
- Values obtained with different assay methods or kits cannot be used
- interchangeably. Results cannot be interpreted as absolute evidence
- of the presence or absence of malignant disease.

| | | | |
|-------------|------|-------------|-------|
| F PSA, Free | 0.22 | N/A (ng/mL) | PDLCA |
|-------------|------|-------------|-------|

- Roche ECLIA methodology.

| | | | |
|--------------|------|-----|-------|
| F % Free PSA | 31.4 | (%) | PDLCA |
|--------------|------|-----|-------|

- The table below lists the probability of prostate cancer for
- men with non-suspicious DRE results and total PSA between
- 4 and 10 ng/mL, by patient age (Catalona et al, JAMA 1998,
- 279:1542).

| | % Free PSA | 50-64 yr | 65-75 yr |
|---|--------------|----------|----------|
| - | 0.00-10.00% | 56% | 55% |
| - | 10.01-15.00% | 24% | 35% |
| - | 15.01-20.00% | 17% | 23% |

- 20.01-25.00% 10% 20%
- >25.00% 5% 9%

- Please note: Catalona et al did not make specific
- recommendations regarding the use of
- percent free PSA for any other population
- of men.

F PDF

.

TG